Table 1.
Characteristics of the subjects included in the studies.
| Author, year | Study design | Duration | Study group | N | Mean age (years) | Baseline values (mg/dl) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Triglycerides | TC | LDL-c | HDL-c | FBG | HbA1c (%) | ||||||
| Adibian et al., 2019 [20] | RDP | 10 weeks | Curcumin 1500 mg/d | 21 | 58 ± 8 | 124 ± 36 | 167 ± 34 | 112 ± 31 | 30 ± 2 | 160 ± 35 | 11.3 ± 1.6 |
| Placebo | 23 | 60 ± 7 | 126 ± 52 | 180 ± 47 | 125 ± 44 | 30 ± 2 | 144 ± 40.6 | 11.2 ± 1.3 | |||
| Adab et al., 2019 [21] | RDP | 8 weeks | Turmeric 2100 mg/d | 39 | 54.76 ± 6.00 | 181.56 ± 79.79 | 148.85 ± 36.11 | 82.56 ± 20.99 | 38.79 ± 10.30 | 133.79 ± 25.60 | 7.06 ± 1.01 |
| Placebo | 36 | 55.66 ± 8.64 | 164.05 ± 81.19 | 155.36 ± 36.27 | 86.61 ± 21.99 | 44.63 ± 10.66 | 129.91 ± 32.98 | 6.79 ± 1.08 | |||
| Abbood, 2018 [22] | RP | 12 weeks | Curcumin 1000 mg/d | 16 | 46.76 ± 7.89 | 193.15 ± 59.36 | 214.18 ± 60.31 | 109.02 ± 12.76 | 46.01 ± 9.28 | 190.44 ± 51.48 | 8.0 ± 0.91 |
| Atorvastatin 20 mg/d | 16 | 225.93 ± 135.56 | 262.5 ± 68.43 | 114.43 ± 53.74 | 53.74 ± 9.67 | 214.56 ± 57.96 | 8.19 ± 1.24 | ||||
| Placebo | 16 | 170.11 ± 73.54 | 223.07 ± 48.33 | 105.16 ± 39.43 | 38.27 ± 11.6 | 210.24 ± 65.52 | 8.35 ± 1.93 | ||||
| Panahi et al., 2017 [12] | RDP | 12weeks | Curcuminoids 1000 mg/d | 50 | 43 ± 8 | 229.78 ± 81.84 | 217.34 ± 41.60 | 169.16 ± 30.77 | 40.86 ± 5.41 | 163 ± 37 | 7.4 ± 0.7 |
| Placebo | 50 | 41 ± 7 | 207.62 ± 54.63 | 231.04 ± 70.95 | 199.06 ± 54.49 | 39.46 ± 6.09 | 174 ± 32 | 7.5 ± 0.9 | |||
| Rahimi et al., 2016 [11] | RDP | 3 months | Nano-curcumin 80 mg/d | 35 | 56.34 ± 11.17 | 109 (94.75) # | 163.4 ± 33.94 | 96.57 ± 33.94 | 54.30 ± 14.02 | 135.5 ± 51.33 | 7.59 ± 1.74 |
| Placebo | 35 | 60.95 ± 10.77 | 142 (97.50) # | 162.4 ± 38.59 | 99.78 ± 30.33 | 60.35 ± 15.96 | 148.30 ± 76.41 | 7.49 ± 1.75 | |||
| Maithili et al., 2015 [23] | RP | 4 weeks | Turmeric 2 g/d + Met 1 g/d | 30 | 47 ± 7.17 | 120.56 ± 37.1 | 184.6 ± 14.6 | 124.4 ± 17 | 36.02 ± 8.1 | 116 ± 23 | 7.9 ± 1.3 |
| Met 1 g/d | 30 | 46.8 ± 6.1 | 127.3 ± 33.3 | 181.5 ± 22.3 | 121.7 ± 26.3 | 34.3 ± 7.1 | 111 ± 24 | 7.8 ± 0.5 | |||
| Na et al., 2013 [15] | RDP | 3 months | Curcuminoids 300 mg/d | 50 | 55.42 ± 6.40 | 2.23 ± 0.53 | 6.11 ± 1.13 | 4.30 ± 1.20 | 1.37 ± 0.26 | 8.58 ± 2.66 | 7.77 ± 1.82 |
| Placebo | 50 | 54.72 ± 8.34 | 2.19 ± 1.04 | 6.08 ± 1.24 | 4.32 ± 1.15 | 1.33 ± 0.28 | 8.41 ± 2.17 | 7.72 ± 2.12 | |||
| Khajehdehi et al., 2011 [24] | RDP | 2 months | Turmeric 1500 mg/d | 20 | 52.9 ± 9.2 | 236.2 ± 146.5 | 214.2 ± 66.5 | 114.1 ± 34.6 | 43.8 ± 12.6 | 179.0 ± 65.5 | |
| Placebo | 20 | 52.6 ± 9.7 | 220.4 ± 106.9 | 193.3 ± 45.7 | 108.3 ± 39.9 | 39.8 ± 9.5 | 169.54 ± 76.3 | ||||
| Usharani et al., 2008 [14] | RDP | 8 weeks | Curcuminoids 600 mg/d | 23 | 55.52 ± 10.76 | 176.39 ± 27.61 | 195.0 ± 41.16 | 120.35 ± 42.13 | 38.78 ± 7.69 | 155.04 ± 17.94 | 8.04 ± 0.85 |
| Atorvastatin 10 mg/d | 23 | 50.47 ± 10.35 | 182.26 ± 43.85 | 196.78 ± 35.28 | 123.50 ± 38.73 | 36.82 ± 5.45 | 161.21 ± 19.74 | 8.30 ± 0.86 | |||
| Placebo | 21 | 49.75 ± 8.18 | 170.14 ± 47.54 | 196.95 ± 35.72 | 125.29 ± 34.94 | 36.38 ± 7.67 | 161.19 ± 19.97 | 7.82 ± 0.57 | |||
Values are expressed as mean ± SD. #Values expressed as Median (IQR).